168 related articles for article (PubMed ID: 11489810)
1. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers.
Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
Clin Cancer Res; 2001 Aug; 7(8):2340-3. PubMed ID: 11489810
[TBL] [Abstract][Full Text] [Related]
2. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.
Halmos G; Arencibia JM; Schally AV; Davis R; Bostwick DG
J Urol; 2000 Feb; 163(2):623-9. PubMed ID: 10647698
[TBL] [Abstract][Full Text] [Related]
3. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.
Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y
Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
5. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer.
Straub B; Müller M; Krause H; Schrader M; Miller K
Urology; 2003 Jul; 62(1):172-6. PubMed ID: 12837461
[TBL] [Abstract][Full Text] [Related]
6. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
Rozsa B; Nadji M; Schally AV; Dezso B; Flasko T; Toth G; Mile M; Block NL; Halmos G
Prostate; 2011 Apr; 71(5):445-52. PubMed ID: 20859992
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone receptor expression in the human prostate.
Tieva A ; Stattin P; Wikström P; Bergh A; Damber JE
Prostate; 2001 Jun; 47(4):276-84. PubMed ID: 11398175
[TBL] [Abstract][Full Text] [Related]
10. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
11. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
Irmer G; Bürger C; Müller R; Ortmann O; Peter U; Kakar SS; Neill JD; Schulz KD; Emons G
Cancer Res; 1995 Feb; 55(4):817-22. PubMed ID: 7850795
[TBL] [Abstract][Full Text] [Related]
12. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
[TBL] [Abstract][Full Text] [Related]
13. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.
Ishiguro H; Nakaigawa N; Miyoshi Y; Fujinami K; Kubota Y; Uemura H
Prostate; 2005 Jun; 64(1):92-100. PubMed ID: 15666359
[TBL] [Abstract][Full Text] [Related]
14. Expression of ERalpha and ERbeta in prostate cancer.
Linja MJ; Savinainen KJ; Tammela TL; Isola JJ; Visakorpi T
Prostate; 2003 May; 55(3):180-6. PubMed ID: 12692783
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
16. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer.
Segawa Y; Yoshimura R; Hase T; Nakatani T; Wada S; Kawahito Y; Kishimoto T; Sano H
Prostate; 2002 May; 51(2):108-16. PubMed ID: 11948965
[TBL] [Abstract][Full Text] [Related]
17. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
Avgeris M; Koutalellis G; Fragoulis EG; Scorilas A
Clin Biochem; 2008 Oct; 41(14-15):1140-9. PubMed ID: 18586020
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
19. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines.
Dizeyi N; Bjartell A; Nilsson E; Hansson J; Gadaleanu V; Cross N; Abrahamsson PA
Prostate; 2004 May; 59(3):328-36. PubMed ID: 15042609
[TBL] [Abstract][Full Text] [Related]
20. Alteration of gonadotropin-releasing hormone receptor expression with the progression of prostate cancer in the Dunning rat adenocarcinoma sublines.
Tieva A; Bergh A; Damber JE
Acta Oncol; 2005; 44(3):299-303. PubMed ID: 16076703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
